Clinical Trials Logo

Clinical Trial Summary

Randomised, double blind, Phase 2 Trial to evaluate the efficacy of oral Capsaicin in patients with post-stroke dysphagia in the (sub-)acute setting.


Clinical Trial Description

After inclusion and the assessment of the swallowing function (PRESS, PAS, FOIS, FEES) patients will be randomised 1:1 to receive 1mcg Capsaicin or Placebo. Oral treatment will be applied 3 times daily either during meals or during regular swallowing tests/trainings accompanied by a Speech Language Pathologist. After re-assessment of the dysphagia after 7 days, patients with persistent dysphagia and applicable for further treatment will be treated for another 23 days with a final clinical swallowing evaluation after a total of 30 days. A Patient Medication Diary will used during the Duration of the Trial to capture compliance. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04470752
Study type Interventional
Source Cantonal Hospital of St. Gallen
Contact Georg Kägi, Dr.med.
Phone +41 71 494 3594
Email georg.kaegi@kssg.ch
Status Recruiting
Phase Phase 2
Start date August 24, 2021
Completion date December 2024

See also
  Status Clinical Trial Phase
Completed NCT03247374 - Bio-feedback Treatment for Dysphagic Post-stroke Patients N/A
Recruiting NCT04695600 - Onabotulinum Toxin A (Botox) in the Treatment of Transfer Dysphagia Phase 2/Phase 3
Completed NCT04347863 - Investigating Program of Food Preparation on Diet Improvement for Patients With Stroke N/A